The UK and US have signed a significant trade agreement that will keep no duties on British pharmaceutical shipments being sold in the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost funding on pharmaceuticals through the public health system. This commitment secures that duties on these vital exports will stay at zero for a period of three years.
This agreement comes after earlier threats to hike duties on patented drug products, with potential rates mentioned as high as double the cost.
"This agreement between the Britain strengthens the global environment for cutting-edge drugs and establishes long-overdue equity to transatlantic medicine commerce," a release noted.
Trade Importance
Pharmaceuticals are one of the UK's largest exports to the United States, which is by far the primary destination for major British pharmaceutical firms.
Trade data indicate that in the 12 months prior to last September, the UK shipped medicines totaling £11.1bn to the US. This amount made up 17.4% of total UK exports in that timeframe.
"This deal secures employment, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Key NHS Changes
The pact entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase overall NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, refunds exceeded 20%.
Broader Context
The deal follows a ongoing row between the sector and the British authorities over drug pricing and approval rates.
The disagreement were intensified by claims that American consumers were paying a premium for the identical medicines than consumers in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar investments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
